NCT05109052

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Withdrawn Phase 1, PHASE2 Last updated 13 July 2023

What this trial tests

Phase 1, PHASE2 trial testing PXS-5505 and Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Withdrawn.

Timeline

20 September 2022

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	University of Rochester
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	20 September 2022
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across United States

Drugs / interventions tested

• PXS-5505 and Atezolizumab and Bevacizumab — full drug profile →

Conditions studied

• Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
• Cancer of Liver — all drugs for Cancer of Liver →

Sponsor

University of Rochester

Who can join

18 and older, any sex, with Hepatocellular Carcinoma or Cancer of Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will assess the safety and tolerability of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab in unresectable or metastatic hepatocellular carcinoma. Phase 2 will assess the efficacy of this combination therapy in unresectable or metastatic hepatocellular carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics.
   Prakash J, Shaked Y. · · 2024 · cited 201× · PMID 39091205 · DOI 10.1158/2159-8290.cd-24-0002
2. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy.
   Hu Q, Zhu Y, Mei J, Liu Y, et al · · 2025 · cited 54× · PMID 40537775 · DOI 10.1186/s13045-025-01717-y
3. Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy.
   Xiong J, Xiao R, Zhao J, Zhao Q, et al · · 2024 · cited 39× · PMID 38246995 · DOI 10.1186/s12967-023-04810-3
4. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis.
   Yao Y, Findlay A, Stolp J, Rayner B, et al · · 2022 · cited 36× · PMID 35628342 · DOI 10.3390/ijms23105533
5. Lysyl Oxidase Family Proteins: Prospective Therapeutic Targets in Cancer.
   Wang W, Wang X, Yao F, Huang C. · · 2022 · cited 32× · PMID 36293126 · DOI 10.3390/ijms232012270
6. Multiple aspects of matrix stiffness in cancer progression.
   Mancini A, Gentile MT, Pentimalli F, Cortellino S, et al · · 2024 · cited 30× · PMID 39015505 · DOI 10.3389/fonc.2024.1406644
7. Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment.
   Liu Y, Yang H, Li T, Zhang N. · · 2024 · cited 23× · PMID 39295859 · DOI 10.3389/fimmu.2024.1460282
8. Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications.
   Peng H, Chao Z, Wang Z, Hao X, et al · · 2025 · cited 21× · PMID 39799341 · DOI 10.1186/s40164-024-00591-7